These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 9083470)

  • 1. Design of highly potent noncovalent thrombin inhibitors that utilize a novel lipophilic binding pocket in the thrombin active site.
    Tucker TJ; Lumma WC; Mulichak AM; Chen Z; Naylor-Olsen AM; Lewis SD; Lucas R; Freidinger RM; Kuo LC
    J Med Chem; 1997 Mar; 40(6):830-2. PubMed ID: 9083470
    [No Abstract]   [Full Text] [Related]  

  • 2. Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position.
    Tucker TJ; Brady SF; Lumma WC; Lewis SD; Gardell SJ; Naylor-Olsen AM; Yan Y; Sisko JT; Stauffer KJ; Lucas BJ; Lynch JJ; Cook JJ; Stranieri MT; Holahan MA; Lyle EA; Baskin EP; Chen IW; Dancheck KB; Krueger JA; Cooper CM; Vacca JP
    J Med Chem; 1998 Aug; 41(17):3210-9. PubMed ID: 9703466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
    Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
    J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches.
    Bhunia SS; Roy KK; Saxena AK
    J Chem Inf Model; 2011 Aug; 51(8):1966-85. PubMed ID: 21761917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refined 2.3 A X-ray crystal structure of bovine thrombin complexes formed with the benzamidine and arginine-based thrombin inhibitors NAPAP, 4-TAPAP and MQPA. A starting point for improving antithrombotics.
    Brandstetter H; Turk D; Hoeffken HW; Grosse D; Stürzebecher J; Martin PD; Edwards BF; Bode W
    J Mol Biol; 1992 Aug; 226(4):1085-99. PubMed ID: 1518046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based design of residue 1 analogs of the direct thrombin inhibitor pentapeptide FM 19.
    Girnys EA; Sobczyk-Kojiro K; Mosberg HI
    Chem Biol Drug Des; 2010 Jan; 75(1):35-9. PubMed ID: 19954432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural analysis of thrombin complexed with potent inhibitors incorporating a phenyl group as a peptide mimetic and aminopyridines as guanidine substitutes.
    Bone R; Lu T; Illig CR; Soll RM; Spurlino JC
    J Med Chem; 1998 Jun; 41(12):2068-75. PubMed ID: 9622548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Think twice: understanding the high potency of bis(phenyl)methane inhibitors of thrombin.
    Baum B; Muley L; Heine A; Smolinski M; Hangauer D; Klebe G
    J Mol Biol; 2009 Aug; 391(3):552-64. PubMed ID: 19520086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The crystal structures of human alpha-thrombin complexed with active site-directed diamino benzo[b]thiophene derivatives: a binding mode for a structurally novel class of inhibitors.
    Chirgadze NY; Sall DJ; Briggs SL; Clawson DK; Zhang M; Smith GF; Schevitz RW
    Protein Sci; 2000 Jan; 9(1):29-36. PubMed ID: 10739244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of combinatorial libraries and protein engineering to the discovery of novel anti-thrombotic drugs.
    Leung LL
    Thromb Haemost; 1995 Jul; 74(1):373-6. PubMed ID: 8578488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent noncovalent thrombin inhibitors that utilize the unique amino acid D-dicyclohexylalanine in the P3 position. Implications on oral bioavailability and antithrombotic efficacy.
    Tucker TJ; Lumma WC; Lewis SD; Gardell SJ; Lucas BJ; Baskin EP; Woltmann R; Lynch JJ; Lyle EA; Appleby SD; Chen IW; Dancheck KB; Vacca JP
    J Med Chem; 1997 May; 40(11):1565-9. PubMed ID: 9171866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urethanyl-3-amidinophenylalanine derivatives as inhibitors of factor Xa. X-ray crystal structure of a trypsin/inhibitor complex and modeling studies.
    Sperl S; Bergner A; Stürzebecher J; Magdolen V; Bode W; Moroder L
    Biol Chem; 2000 Apr; 381(4):321-9. PubMed ID: 10839461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.
    Katz BA; Elrod K; Luong C; Rice MJ; Mackman RL; Sprengeler PA; Spencer J; Hataye J; Janc J; Link J; Litvak J; Rai R; Rice K; Sideris S; Verner E; Young W
    J Mol Biol; 2001 Apr; 307(5):1451-86. PubMed ID: 11292354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide.
    Lee K; Park CW; Jung WH; Park HD; Lee SH; Chung KH; Park SK; Kwon OH; Kang M; Park DH; Lee SK; Kim EE; Yoon SK; Kim A
    J Med Chem; 2003 Aug; 46(17):3612-22. PubMed ID: 12904065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, parallel synthesis, and crystal structures of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex.
    Parlow JJ; Case BL; Dice TA; Fenton RL; Hayes MJ; Jones DE; Neumann WL; Wood RS; Lachance RM; Girard TJ; Nicholson NS; Clare M; Stegeman RA; Stevens AM; Stallings WC; Kurumbail RG; South MS
    J Med Chem; 2003 Sep; 46(19):4050-62. PubMed ID: 12954058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel non-covalent thrombin inhibitors incorporating P(1) 4,5,6,7-tetrahydrobenzothiazole arginine side chain mimetics.
    Marinko P; Krbavcic A; Mlinsek G; Solmajer T; Bakija AT; Stegnar M; Stojan J; Kikelj D
    Eur J Med Chem; 2004 Mar; 39(3):257-65. PubMed ID: 15051174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compounds binding to the S2-S3 pockets of thrombin.
    Nilsson M; Hämäläinen M; Ivarsson M; Gottfries J; Xue Y; Hansson S; Isaksson R; Fex T
    J Med Chem; 2009 May; 52(9):2708-15. PubMed ID: 19371038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based design of amidinophenylurea-derivatives for factor VIIa inhibition.
    Klingler O; Matter H; Schudok M; Donghi M; Czech J; Lorenz M; Nestler HP; Szillat H; Schreuder H
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3715-20. PubMed ID: 15203149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological activity of novel rigid amidino-phenylalanine derivatives as inhibitors of thrombin.
    Mack H; Pfeiffer T; Hornberger W; Böhm HJ; Höffken HW
    J Enzyme Inhib; 1995; 9(1):73-86. PubMed ID: 8568568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine.
    Stürzebecher J; Prasa D; Hauptmann J; Vieweg H; Wikström P
    J Med Chem; 1997 Sep; 40(19):3091-9. PubMed ID: 9301673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.